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A B S T R A C T
Purpose
Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor,
platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled
phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and
cytokine-pretreated patients with advanced renal cell carcinoma (RCC).
Patients and Methods
Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned
2:1 to receive oral pazopanib or placebo. The primary end point was progression-free survival
(PFS). Secondary end points included overall survival, tumor response rate (Response Evaluation
Criteria in Solid Tumors), and safety. Radiographic assessments of tumors were indepen-
dently reviewed.
Results
Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated
(46%). PFS was significantly prolonged with pazopanib compared with placebo in the overall study
population (median, PFS 9.2 v 4.2 months; hazard ratio [HR], 0.46; 95% CI, 0.34 to 0.62;
P  .0001), the treatment-naive subpopulation (median PFS 11.1 v 2.8 months; HR, 0.40; 95% CI,
0.27 to 0.60; P  .0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2
months; HR, 0.54; 95% CI, 0.35 to 0.84; P  .001). The objective response rate was 30% with
pazopanib compared with 3% with placebo (P  .001). The median duration of response was
longer than 1 year. The most common adverse events were diarrhea, hypertension, hair color
changes, nausea, anorexia, and vomiting. There was no evidence of clinically important differ-
ences in quality of life for pazopanib versus placebo.
Conclusion
Pazopanib demonstrated significant improvement in PFS and tumor response compared with
placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC.
J Clin Oncol 28:1061-1068. © 2010 by American Society of Clinical Oncology
INTRODUCTION
In the United States, there were 39,226 new cases of
renal cell carcinoma (RCC) and 10,662 deaths esti-
mated in 2008.1 In the European Union, RCC ac-
counts for approximately 3% of all cancers in males
and 2% in females.2 Approximately 90% of kidney
cancers are RCCs, and 70% to 80% of these are of
clear-cell histology.3,4
Renal cell carcinoma is inherently resistant to
cytotoxic therapy, radiation, or hormone therapy.4-6
Before the recent advent of angiogenesis inhibi-
tors, cytokine-based therapy including interferon-
(IFN-) and/or interleukin-2 (IL-2) were the main-
stay of treatment for advanced RCC, despite limited
clinical activity and significant toxicity.5,6 Advances
in the understanding of RCC tumor biology, in-
cluding the role of vascular endothelial growth
factor and mammalian target of rapamycin path-
ways, led to the successful clinical development of
several agents including sorafenib,7 sunitinib,8,9 be-
vacizumab (plus IFN-),10,11 temsirolimus,12 and
everolimus13 for treatment of RCC.
Pazopanib is an oral angiogenesis inhibitor
targeting vascular endothelial growth factor re-
ceptor, platelet-derived growth factor receptor,
and c-Kit.14-16 Pazopanib is under clinical devel-
opment for the treatment of multiple tumor types
and has demonstrated monotherapy activity in
patients with RCC in phase I/II trials.14-16 This ran-
domized, double-blind, placebo-controlled phase
III study evaluated the efficacy and safety of
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pazopanib monotherapy in treatment-naive and cytokine-pretreated
patients with advanced and/or metastatic RCC.
PATIENTS AND METHODS
Patients
This study initially enrolled patients with advanced and/or metastatic
RCC who had progressed on one prior cytokine-based systemic therapy. The
protocol was subsequently amended to include treatment-naive patients (after
enrollment of seven patients) because of emerging evidence of activity of
angiogenesis inhibitors and decreased use of cytokines in the first-line setting.
Patients without prior systemic therapy could be enrolled provided: they were
living in countries where there were barriers to the access of established ther-
apies such as sunitinib, sorafenib, IFN-, or IL-2 or where cytokines were not
recognized as standard treatment for RCC.
Additional eligibility criteria included a diagnosis of clear-cell or pre-
dominantly clear-cell histology; measurable disease per Response Evaluation
Criteria in Solid Tumors17; age  18 years; an Eastern Cooperative Oncology
Group (ECOG) performance status (PS)  1; and adequate renal, hepatic, and
hematologic function. Patients were excluded if they had CNS metastasis;
leptomeningeal lesions; poorly controlled hypertension (systolic blood pres-
sure of  140 mmHg or diastolic blood pressure of  90 mmHg, despite
antihypertensive therapy); QTc interval  470 milliseconds; or a history of the
following cardiac and vascular conditions within 6 months of screening: class
III/IV congestive heart failure per New York Heart Association classification,
cardiac angioplasty or stenting, myocardial infarction, unstable angina, or
cerebrovascular accident. The study was approved by local institutional review
boards and conducted in accordance with Good Clinical Practice guidelines
and the Declaration of Helsinki. All patients provided written informed con-
sent before study-related procedures were performed.
Study Design
Study VEG105192 (clinicaltrials.gov identifier NCT00334282) was a
placebo-controlled, randomized, double-blind, global, multicenter, phase III
study. Randomization was stratified on the basis of ECOG PS (0 v 1), prior
nephrectomy (yes v no), and prior systemic treatment for advanced RCC
(treatment naive v cytokine pretreated). Patients were centrally randomly
assigned in a 2:1 ratio to receive either 800 mg pazopanib once daily or
matching placebo. Study medications were administered orally 1 hour before
or 2 hours after meals. Dose modification guidelines for adverse events (AEs)
were prespecified.
Patients received continuous treatment until disease progression, death,
unacceptable toxicity, or withdrawal of consent for any reason. Subsequent
anticancer therapy for patients with progressive disease was at the discretion of
the patients and their physicians. Patients who progressed were unblinded,
and if found to be on placebo, had the option of receiving pazopanib via an
open-label study (VEG107769), provided they met predefined eligibility crite-
ria. Seventy (48%) of 145 placebo-arm patients enrolled in VEG107769. An
independent data-monitoring committee was established to monitor safety
and review interim overall survival data.
End Points and Assessments
The primary end point was progression-free survival (PFS), defined as
the time interval between the date of random assignment and the date of
progression or death. The principal secondary end point was overall survival
(OS), defined as the time interval between the date of random assignment and
date of death. Other secondary end points included confirmed objective re-
sponse rate (complete response [CR] plus partial response [PR]), duration of
response, and safety. Health-related quality of life (HRQoL) was also assessed.
Disease assessments using computed tomography or magnetic reso-
nance imaging were performed at baseline, every 6 weeks until week 24, and
every 8 weeks thereafter until progression. Bone scans were performed at least
every 24 weeks in all patients and on confirmation of objective response.
Objective responses were confirmed at the next scheduled disease-assessment
visit. Patients who discontinued study treatment before disease progression
were to continue disease assessments until progression or initiation of an
alternate anticancer treatment. All imaging scans were evaluated by an inde-
pendent imaging-review committee (IRC) blinded to study treatment. Tumor
response evaluations by the investigators and the IRC were based on Response
Evaluation Criteria in Solid Tumors.17 Follow-up for OS was performed every
3 months after disease progression until death or study withdrawal.
Clinical assessments for safety, including physical examinations, vital
signs (with blood pressure monitoring), clinical laboratory evaluations, ECG,
ECOG PS, and AEs, were evaluated at baseline, day 8, every 3 weeks until week
24, and every 4 weeks thereafter until study treatment discontinuation. Thy-
roid function tests were performed every 12 weeks and if thyroid-stimulating
hormone levels were abnormal, evaluations of free triiodothyronine/thyroxine
Discontinued study treatment (n = 227; 78%)
Reason for discontinuation
  Disease progression (n = 147; 51%)
  Death (n = 11; 4%)
  AE* (n = 41; 14%)
  Protocol violation (n = 2; < 1%)
  Investigator decision (n = 8; 3%)
  Lost to follow-up, withdrew 
   consent, and other (n = 18; 6%)
Randomly assigned to pazopanib (n = 290)
  Received pazopanib (n = 290)
Randomly assigned to blinded 
treatment with pazopanib and
placebo in a 2:1 ratio
(N = 435)
Randomly assigned to placebo (n = 145)
  Received placebo (n = 145)
Discontinued study treatment (n = 131; 90%)
Reason for discontinuation
  Disease progression (n = 112; 77%)
  Death (n = 9; 6%)
  AE* (n = 5; 3%)
  Investigator decision (n = 1; < 1%)
  Lost to follow-up, withdrew 
    consent, and other (n = 4; 3%)
Analyzed for PFS (n = 290)
Analyzed for safety (n = 290)
Analyzed for PFS (n = 145)
Analyzed for safety (n = 145)
Fig 1. CONSORT diagram. AE, adverse
event; PFS, progression-free survival. (*)
This does not include three patients who,
in addition to AEs, had concurrent other
reasons at the time they discontinued
participation in the study.
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were obtained. Adverse events were graded according to National Cancer
Institute Common Toxicity Criteria for Adverse Events version 3.0.18
Patient-reported HRQoL was assessed using the European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30 version 3) and the EuroQol (EQ-5D) questionnaires at baseline and
at weeks 6, 12, 18, 24, and 48.
Statistical Methods and Analysis
Target enrollment and event requirements were defined to provide at
least 90% power to detect an 80% improvement (hazard ratio [HR], 0.56) in
PFS (primary end point) and 90% power to detect a 50% improvement (HR,
0.67) in OS (secondary end point). After the amendment to include treatment-
naive patients, PFS event requirements were amended to additionally provide
approximately 80% power to detect an 80% improvement (HR, 0.56) or 90%
power to detect a 100% improvement (HR, 0.5) in PFS in each subpopulation
(ie, treatment naive and cytokine pretreated).
There were no planned (or unplanned) interim analyses for PFS. An
interim analysis of OS was to be performed at the time of the final PFS analysis.
Thus, the sample size calculation for OS included one planned interim analysis
(after 70% of the required deaths) using flexible O’Brien-Fleming type error
spending functions for superiority and futility. All sample size calculations
were performed assuming a one-sided 2.5%  and a 2:1 randomization.
Based on the above requirements, final PFS analysis was planned to be
performed after at least 90 PFS events (by IRC) in each subpopulation and at
least 160 deaths; final analysis of OS was planned to be performed after 287
deaths. The resulting planned enrollment of the study was a total of 400
patients with 150 to 250 patients in each subpopulation.
Efficacy end points were analyzed in all patients randomized to a treat-
ment arm according to the intention-to-treat principle. Safety analyses were
performed on the basis of the actual treatment received in patients who were
randomized and received  one dose of investigational product.
Kaplan-Meier methods were used to analyze PFS and OS. Comparisons
between arms were made using a log-rank test (one sided) stratified by ECOG
PS and prior therapy. Hazard ratios were calculated using a stratified Pike
estimator utilizing the same factors. The primary analysis of PFS was based on
IRC assessments. Progression and censoring dates for the primary analysis
were assigned to the visit time point for scheduled visits. Progressions found at
unscheduled visits were assigned to the next scheduled visit time point to
adjust for any unplanned deviations from the protocol-defined visit schedule,
as agreed to with the United States Food and Drug Administration during the
study-design process. Nine predefined sensitivity analyses of PFS were per-
formed to confirm the robustness of the primary result using various assump-
tions, including alternate definitions of progression and censoring dates, data
sources (IRC v investigator), and analysis methods. Comparison of PFS be-
tween treatment arms was done using the log-rank test in predefined subgroup
analyses based on prior treatment, age, sex, Memorial Sloan-Kettering Cancer
Center (MSKCC) risk group,19 and ECOG PS. Approximate 95% CIs for
response rate (RR) differences were calculated. Duration of response and time
to response were summarized descriptively using medians and quartiles.
A mixed-model repeated-measures analysis of change from baseline was
performed for QoL measures that were collected by blinded patient self-
reports using the EORTC QLQ-C30 and EQ-5D questionnaires.20,21 The key
end points for these analyses were summary scores from these questionnaires
that included the EORTC QLQ-Global Health Status/QoL Score, EQ-5D
Index, and EQ-5D visual analog scale (VAS). The minimal important differ-
ences (MID) for these questionnaires were previously established as 5 to 10 for
EORTC QLQ-C30,22 0.08 for EQ-5D Index, and 7 for EQ-5D VAS.23
RESULTS
Patients
Of 435 patients with advanced and/or metastatic RCC (233
treatment naive; 202 cytokine pretreated) were enrolled between
April 2006 and April 2007 from 80 centers in Europe, Asia, South
America, North Africa, Australia, and New Zealand; 290 patients
were randomly assigned to pazopanib and 145 were randomly
assigned to placebo.
At the cutoff date (May 23, 2008), 78% of patients in the pazo-
panib arm and 90% of patients in the placebo arm had discontinued
study treatment. Disease progression was the most common reason
for death and discontinuation (Fig 1). Demographic and disease char-
acteristics were well balanced between treatment arms (Table 1). All
patients had clear cell or predominantly clear-cell histology.






No. % No. %
Median age, years 59 60
Range 28-85 25-81
Sex
Male 198 68 109 75
Race
White 252 87 122 84
Asian 36 12 23 16
Black 1  1 0
Other 1  1 0
Histology
Clear cell 264 91 129 89
Predominantly clear cell 25 9 16 11
Median time since initial diagnosis,
months 15.7 13.8
Range 0-184.0 1.0-152
Most common sites of metastasis†
Lung 214 74 106 73
Lymph nodes 157 54 86 59
Bone 81 28 38 26
Liver 75 26 32 22
Kidney 66 23 36 25
No. of organs involved†
1 53 18 20 14
2 78 27 50 34
 3 159 55 75 52
ECOG performance status
0 123 42 60 41
1 167 58 85 59
MSKCC risk category‡
Favorable 113 39 57 39
Intermediate 159 55 77 53
Poor 9 3 5 3
Unknown§ 9 3 6 4
Prior nephrectomy 258 89 127 88
Prior systemic treatment
Treatment naïve 155 53 78 54
Cytokine pretreated 135 47 67 46
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MSKCC, Me-
morial Sloan-Kettering Cancer Center.
Histology at initial diagnosis was missing for one patient in the pazo-
panib arm.
†As defined by the investigator.
‡One hundred eight of the MSKCC risk group assignments required the use
of total calcium measurements because of missing baseline albumin levels to
calculate corrected calcium.
§Patients with an unknown MSKCC risk category were missing results for
one or more of the five risk criteria.
Pazopanib in Renal Cell Carcinoma
www.jco.org © 2010 by American Society of Clinical Oncology 1063
147.46.155.67
Information downloaded from jco.ascopubs.org and provided by at Seoul National Univ Med Libr on May 16, 2012 from
Copyright © 2010 American Society of Clinical Oncology. All rights reserved.
Efficacy: PFS
At the final PFS analysis, 148 patients progressed on pazopanib
and 98 patients progressed on placebo, based on independent review.
In the treatment-naive and cytokine-pretreated subpopulations, 130
and 116 PFS events were recorded, respectively. Pazopanib signifi-
cantly prolonged PFS compared with placebo in the overall study
population (median PFS, 9.2 v 4.2 months; HR, 0.46; 95% CI, 0.34 to
0.62; P  .0001), the treatment-naive subpopulation (median PFS,
11.1 v 2.8 months; HR, 0.40; 95% CI, 0.27 to 0.60; P  .0001), and the
cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2 months;
HR, 0.54; 95% CI, 0.35 to 0.84; P  .001; Fig 2).
All nine sensitivity analyses of PFS confirmed the primary PFS
result, with HR range of 0.42 to 0.49. In most cases, larger estimates of
treatment effect by pazopanib (ie, lower HRs) were observed with the
sensitivity analyses compared with the primary analysis, including PFS
based on investigators’ assessment (HR, 0.44; 95% CI, 0.34 to 0.57;
P  .0001). The prespecified subgroup analyses showed that PFS was
improved for patients treated with pazopanib compared with placebo
regardless of MSKCC risk category, sex, age, or ECOG PS (HR range,
0.40 to 0.52; P  .001 by log-rank test for all; Fig 3).
Tumor Response
The RR (by independent review) for pazopanib-treated patients
in the overall study population was 30% (95% CI, 25.1 to 35.6), with a
median duration of response of 58.7 weeks. A similar RR was seen in
pazopanib-treated patients in the treatment-naive (32%) and
cytokine-pretreated (29%) populations (Table 2). The investigator-
assessed RR in the overall population (36%; 95% CI, 30.0 to 41.0;
median duration of response of 62.4 weeks) is consistent with RR
based on independent review.
Interim OS
The interim analysis of OS in the overall study population was
based on 176 death events, which was 61% of the required 287 death
events for the final OS analysis. The interim OS result did not cross the
prespecified O’Brien-Fleming boundaries for either superiority or
futility. Final OS results will be reported when data are mature.
Safety
The median duration of exposure to treatment was approxi-
mately double in the pazopanib arm compared with placebo (7.4 v 3.8
months). At the time of data cutoff, 32% of patients on pazopanib and
15% of patients on placebo had received treatment for more than
12 months.
Most AEs were grade 1/2 (Table 3). Diarrhea (52%), hyperten-
sion (40%), hair color changes (38%), nausea (26%), anorexia (22%),
and vomiting (21%) were the most common AEs reported in the
pazopanib arm. Proportions of patients experiencing an AE with
maximum grade of 3 or 4 were 33% and 7%, respectively, in the
pazopanib arm compared with 14% and 6%, respectively, in the
placebo arm. The most common grade 3/4 AEs in the pazopanib arm
were hypertension (4%) and diarrhea (4%). The AE profile was sim-
ilar in treatment-naive and cytokine-pretreated patients, although
discontinuation rates because of AEs were higher in cytokine-
pretreated (19%) compared with treatment-naive (12%) patients.
Arterial thrombotic events occurred in 3% of pazopanib-treated
patients (myocardial infarction/ischemia [2%], cerebrovascular acci-
dent [ 1%], and transient ischemic attack [ 1%]) compared with
none in the placebo arm. The incidence of hemorrhagic events (all
grades) in the pazopanib arm was 13% compared with 5% in the
placebo arm.
Most laboratory abnormalities were grade 1/2 (Table 3). The
most common clinical laboratory abnormalities observed in the pazo-






























No. patients at risk
Pazopanib 290 159 76 29 6
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Pazopanib 155 84 39 11 1






























No. patients at risk
Pazopanib 135 75 37 18 5
Placebo 67 16 7 
Fig 2. Kaplan-Meier survival curve of progression-free survival (PFS) by inde-
pendent review in (A) overall study population, (B) treatment-naive population,
and (C) cytokine-pretreated population. The difference in median PFS between
cytokine-naive and cytokine-pretreated placebo patients is an artifact of the
visit-based analysis.
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ALT  3 the upper limit of normal occurred in 52 pazopanib-
treated patients (18%): ALT elevation recovered to  grade 1 after
dose modification, interruption, or discontinuation in 45 patients
(87%); seven patients (13%) did not have adequate follow-up data to
assess recovery.
Death resulting from AEs was reported in 4% of patients in the
pazopanib arm and 3% of patients in the placebo arm. Four patients
(1%) in the pazopanib arm had fatal AEs that were assessed by the
investigator as attributable to study treatment: ischemic stroke, abnor-
mal hepatic function and rectal hemorrhage, peritonitis/bowel perfo-
ration, and abnormal hepatic function (one patient each). The patient
who died of peritonitis/bowel perforation had RCC metastasis present
at the site of perforation. The later patient who died of abnormal
hepatic function was found on autopsy to have extensive infiltration of
the liver with metastatic disease.
HRQoL
Completion rates for QoL questionnaires were high across
most of the assessment timepoints for each instrument ( 90%).
The longitudinal means for the three QoL end points showed a trend
for maintenance of QoL across time between treatment and placebo
groups, with differences that were not clinically important according
to established MID for the questionnaires. The mixed-model
repeated-measures analyses showed no statistical differences between
pazopanib and placebo at any of the assessment time points for the
three key QoL end points (Table 4). There was a difference in the rate
of withdrawal of patients from the placebo arm because of disease
progression, which became apparent after week 6 and was especially
evident at later assessment timepoints.
DISCUSSION
In this phase III trial, pazopanib demonstrated a significant improve-
ment in PFS and RR compared with placebo in patients with advanced
and/or metastatic RCC in the overall population and in the treatment-
naive and cytokine-pretreated subpopulations. The efficacy of pazo-
panib observed in this study confirms results observed in a previous
phase II trial in patients with advanced RCC (VEG102616; median
PFS, 11.9 months; RR, 35%; median duration of response, 68
weeks).16 The effects of PFS and RR in the treatment-naive subpopu-
lation observed in this phase III trial are comparable to published data
for sunitinib and bevacizumab (with IFN-).8,10,11
When this study was initiated in April 2006, limited access to the
multikinase inhibitors sunitinib and sorafenib precluded the use of
either as a comparator. Therefore, placebo with best supportive care
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281Age < 65 yrs
154Age ≥ 65 yrs
183ECOG PS 0
252ECOG PS 1
Fig 3. Predefined subgroup analysis of
progression-free survival per independent
review. MSKCC, Memorial Sloan-Kettering
Cancer Center; ECOG PS, Eastern Cooper-
ative Oncology Group performance status.






No. % No. %
Overall study population
Best response
Complete response 1  1 0
Partial response 87 30 5 3
Stable disease 110 38 59 41
Progressive disease 51 18 58 40
Unknown 41 14 23 16
Response rate (CR  PR) 88† 30 5 3
95% CI 25.1 to 35.6 0.5 to 6.4
Median duration of response, weeks 58.7 —
95% CI 52.1 to 68.1 —
Median time to response, weeks 11.9 —
95% CI 9.4 to 12.3 —
Treatment-naive subgroup 155 78
Response rate (CR  PR) 49 32 3 4
95% CI 24.3 to 38.9 0.0 to 8.1
Cytokine-pretreated subgroup 135 67
Response rate (CR  PR) 39 29 2 3
95% CI 21.2 to 36.5 0.0 to 7.1
Abbreviations: CR, complete response; PR, partial response.
A patient was classified as unknown if he or she never had progressive disease
and did not have stable disease for at least 12 weeks (the minimum requirement
to be classified as stable disease). This includes patients with no follow-up and
some patients censored by independent review.
†P  .001, based on Fisher’s exact test comparison of treatment arms.
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patients. In addition, using a placebo control in a randomized double-
blind design enabled better characterization of the safety and efficacy
profile of pazopanib. When the protocol was amended to allow enroll-
ment of treatment-naive patients, placebo with best supportive care
was retained as the control arm. (Criteria for enrolling treatment-
naive patients are described in detail in the Patients and Methods
section.) Moreover, cytokines as a standard of care were being chal-
lenged in some participating countries, based on their unfavorable
risk-benefit profile24,25 and emerging data for multikinase inhibitors.
Exposure of patients to placebo in the study was minimized by 2:1
random assignment, and pazopanib was provided as a treatment
option for patients who progressed on placebo.
Pazopanib demonstrated acceptable safety and tolerability.
Diarrhea, hypertension, hair color changes, nausea, anorexia, and
vomiting were the most commonly reported AEs (incidence of
 20%). Most AEs related to pazopanib treatment were grade 1/2 and
were clinically manageable. The most common grade 3/4 AEs were
hypertension and diarrhea. The most common grade 3/4 chemistry
abnormalities were ALT elevation and AST elevation. Most cases of
drug-induced liver enzyme elevations were asymptomatic and oc-
curred within the first 4 months of treatment. Certain AEs known to
occur with this class of agents, including proteinuria, thrombocytope-
nia, hypothyroidism, hand-foot syndrome, and mucositis/stomatitis,
occurred with an incidence of fewer than 10% each, with grade 3/4
events reported in less than 1% of patients. It is notable in the current
analysis that patients who were treated with pazopanib did not have a
clinically important difference (relative to the MID) in QoL compared
with placebo in blinded patient self-reports, despite toxicities that may
be expected with an active agent. These results are consistent with the
observed tolerability profile for pazopanib, which is particularly im-
portant because patients with RCC are often asymptomatic when
therapy is initiated and may remain on therapy for prolonged periods
of time. Although some AEs observed with pazopanib are related to
target inhibition, others may result from off-target activity. Potential
differences in the safety profiles of multikinase angiogenesis inhibitors
may be explained by differences in the potency and selectivity of
kinases inhibited.26 Pazopanib, although an inhibitor of c-Kit, is not a
potent inhibitor of fms-related tyrosine kinase 3,26 which may explain
the low rate ( 1%) of grade 3/4 cytopenias observed with pazopanib.
In conclusion, once-daily oral pazopanib significantly im-
proved PFS and RR in treatment-naive and cytokine-pretreated
patients with advanced and/or metastatic RCC. Furthermore, pazo-
panib was well tolerated in this population. These findings support the
continued evaluation of the efficacy, safety, and effect on QoL of
pazopanib in this patient population. A phase III trial comparing
pazopanib monotherapy with sunitinib in treatment-naive patients
Table 3. Common Treatment-Emergent Adverse Events and Selected Clinical Laboratory Abnormalities† in Patients With At Least One Adverse Event
Parameter
Grade
Pazopanib (n  290) Placebo (n  145)
Any 3 4 Any  3 4
No. % No. % No. % No. % No. % No. %
Adverse event
Diarrhea 150 52 9 3 2  1 13 9 1  1 0
Hypertension 115 40 13 4 0 15 10 1 1 0
Hair color changes 109 38 1  1 0 4 3 0 0
Nausea 74 26 2  1 0 13 9 0 0
Anorexia 65 22 6 2 0 14 10 1  1 0
Vomiting 61 21 6 2 1  1 11 8 3 2 0
Fatigue 55 19 7 2 0 11 8 2 1 2 1
Asthenia 41 14 8 3 0 12 8 0 0
Abdominal pain 32 11 6 2 0 2 1 0 0
Headache 30 10 0 0 7 5 0 0
Clinical chemistry
ALT increase 152 53 30 10 5 2 32 22 2 1 0
AST increase 152 53 21 7 2  1 27 19 1  1 0
Hyperglycemia 115 41 2  1 0 47 33 2 1 0
Total bilirubin increase 102 36 7 3 2  1 15 10 2 1 1  1
Hypophosphatemia 95 34 11 4 0 16 11 0 0
Hypocalcemia 91 33 4 1 4 1 35 26 2 1 1  1
Hyponatremia 86 31 11 4 4 1 35 24 6 4 0
Hypomagnesemia 31 11 9 3 0 13 9 3 2 0
Hypoglycemia 47 17 0 1  1 4 3 0 0
Hematologic
Leukopenia 103 37 0 0 9 6 0 0
Neutropenia 94 34 3 1 1  1 9 6 0 0
Thrombocytopenia 89 32 2  1 1  1 7 5 0 1  1
Lymphocytopenia 86 31 11 4 1 1 34 24 2 1 0
Adverse events with an incidence of  10% in the pazopanib arm are displayed.
†Clinical laboratory abnormalities with an incidence of  30% in the pazopanib arm or with a 5% increase in incidence in the pazopanib arm compared with the
placebo arm are displayed.
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with advanced and/or metastatic RCC is ongoing (clinicaltrials.gov
identifier NCT00720941).
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6 243 110 1.90 5.84 to 2.04 .34
12 219 81 2.82 7.17 to 1.53 .20
18 191 61 2.05 6.95 to 2.86 .41
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Abbreviations: QoL, quality of life; EORTC QLQ-C30, European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D,
EuroQuol questionnaire; VAS, visual analogue scale.
More patients in the placebo arm discontinued study treatment because of
disease progression compared with patients in the pazopanib arm.
†The minimal important differences for the questionnaires have been
previously established as 5 to 10 for the EORTC-QLQ-C30, 0.08 for the EQ-5D
Index, and 7 for the EQ-5D VAS. Values greater than 0 indicate a trend in favor
of pazopanib, and values less than 0 indicate a trend in favor of placebo.
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